On August 12, 2020O Helix BioPharma Corp. (TSX: HBP) ("Helix" or the "Company"), is a clinicalstage biopharmaceutical company developing unique therapies in the field of immuno-oncology for the prevention and treatment of cancer based on its proprietary technological platform DOS47, reported that it has extended its collaboration agreement with Moffitt Cancer Center ("Moffitt") for an additional year (Press release, Helix BioPharma, AUG 12, 2020, View Source [SID1234563505]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
To date, Helix and Moffitt have developed a new pancreatic adenocarcinoma mouse model suitable for testing the Company’s lead clinical compound L-DOS47 alone or in combination with immunotherapies. Preliminary data includes how L-DOS47 may work with immunotherapy were shown in American Association for Cancer Research (AACR) (Free AACR Whitepaper) ("AACR") Annual Meeting 2019. In addition, in September 2019, at the World Molecular Imaging Conference, the Company and Moffitt jointly presented a poster presentation on the pharmacodynamics of targeted urease and checkpoint blockade using Chemical Exchange Saturation Transfer ("CEST") and 31P-magnetic resonance spectroscopy ("31P-MRS"). The imaging technique is currently being used in the Company’s U.S. clinical study in advanced stage pancreatic patients.
In this next stage, the Company together with Moffit, intends to build on these early successes and provide additional preclinical support in using L-DOS47 with immunotherapies as clinical support.
"I look forward to expanding the use of L-DOS47 in combination with immunotherapy for future clinical application", said Dr. Heman Chao, Helix’s Chief Executive Officer